Drugs / Noradrenaline
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 35 trials | ||||||
| Phase 3 | NCT05014581 | Aug 2024 → Mar 2026 overdue | respiratory failure | University of Turin, Italy | Recruiting | No outcome recorded |
| Phase 3 | NCT05931601 | Dec 2023 → Dec 2026 expected | dehydration polycythemia, hypotensive disorder | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05335954 | Apr 2022 → Dec 2023 | heart disorder, hypotensive disorder | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04569942 | Oct 2021 → Feb 2026 overdue | — | Australian and New Zealand Intensive Care Research Centre | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03822091 | Jan 2019 → Jan 2020 | hepatorenal syndrome | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05168462 | Oct 2022 → Apr 2027 expected | cardiogenic shock, myocardial infarction | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07067944 | Jul 2023 → Mar 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT04376281 | Dec 2019 → Aug 2021 | — | Cairo University | Completed | No outcome recorded |
| — | NCT02573727 | Oct 2015 → Jan 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01649037 | Aug 2012 → Jun 2015 | hepatorenal syndrome | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT00901745 | May 2009 → Apr 2010 | heart disorder, isoproterenol-mediated vasodilatation | University of Edinburgh | Completed | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04586790 Background | Oct 2020 → Jan 2021 | — | Ahmed talaat ahmed aly | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06885268 Comparator | Jun 2025 → Jun 2027 expected | — | Jagiellonian University | Recruiting | No outcome recorded |
| Phase 3 | NCT05207280 Background | Oct 2022 → Nov 2024 | infectious disease with sepsis | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 3 | NCT05481723 Comparator | Jul 2022 → Jul 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT01637454 Comparator | Jan 2009 → Dec 2011 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06265259 Comparator | Dec 2023 → Dec 2025 | — | University of Thessaly | Unknown | No outcome recorded |
| Phase 4 | NCT04701190 Comparator | Feb → Dec 2021 | hypotensive disorder | Ankara University | Completed | No outcome recorded |
| Phase 4 | NCT04243655 Background | Dec 2019 → Oct 2020 | liver disorder | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT00484133 Background | Jun 2007 → Dec 2008 | infectious disease with sepsis | Onze Lieve Vrouwe Gasthuis | Unknown | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07022730 Comparator | Jun → Sep 2025 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| — | NCT06853574 Comparator | Feb → Jun 2025 overdue | infectious disease with sepsis | General and Teaching Hospital Celje | Not yet recruiting | No outcome recorded |
| — | NCT05346393 Comparator | Nov 2022 → Jun 2025 overdue | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | Jena University Hospital | Recruiting | No outcome recorded |
| — | NCT05341167 Background | May 2022 → Nov 2023 | — | Attikon Hospital | Completed | No outcome recorded |
| — | NCT05733403 Comparator | Apr 2022 → Oct 2023 | — | Istanbul University | Unknown | No outcome recorded |
| — | NCT05774054 Comparator | May 2021 → Feb 2023 | hypotensive disorder, infectious disease with sepsis | Tanta University | Completed | No outcome recorded |
| — | NCT03118024 Comparator | Mar 2017 → Mar 2019 | — | University of Regensburg | Unknown | No outcome recorded |
| — | NCT02468063 Comparator | May 2015 → May 2017 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01836224 Comparator | Oct 2012 → Sep 2014 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Noradrenaline | “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗31“The Effect of Oral Midodrine Versus Oral Desmopressin Acetate Use for Liberation From IV Noradrenaline in Intensive Care Unit Patients Recovering From Spinal Shock .” NCT04586790 ↗ “To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure” NCT02573727 ↗ “In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.” NCT05346393 ↗ “commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice” NCT04569942 ↗ “pressor support (noradrenaline, doubutamine, dopamine) as needed” NCT04243655 ↗ “noradrenaline max. 0.15 µg/kg/min” NCT03118024 ↗ “noradrenaline” NCT05341167 ↗ |
| Known as | norepinephrine | “Noradrenaline (or norepinephrine) "is a potent peripheral vasoconstrictor which acts both on arterial and venous substrates (alpha-adrenergic effect) and as a cardiac inotropic...” NCT06265259 ↗ |
| Action | Activate | “Noradrenaline acts as an agonist at α-adrenergic receptors with mild β-agonistic activity.” NCT03822091 ↗ |
| Route | Other | “Infusion of up to 480 picomol/ml of noradrenaline will be infused.” NCT00901745 ↗ |